Abstract
PURPOSE
Women pursuing delayed breast reconstruction (DBR) often wait years before surgery and spend this interval living with a mastectomy defect. This study compared psychosocial, and sexual well-being between women awaiting DBR, and women who received IBR with expander-implants at comparable time points post-mastectomy.
METHODS:
Eligible patients were identified from a prospectively maintained database of patients who completed the BREAST-Q, a patient-reported outcome measure for breast surgery, between March 2011 and December 2012. Patients were matched based on age at the time of mastectomy, body mass index (BMI), and the time interval between mastectomy and BREAST-Q administration, which was either between mastectomy and DBR, or after mastectomy with IBR. The BREAST-Q was completed at least 6 months after mastectomy alone/mastectomy with IBR. The dependent variables were the BREAST-Q Psychosocial well-being score, and the BREAST-Q Sexual well-being score. Univariate analysis and clinical judgment were used to identify variables included in the model. Multivariate linear regression models were constructed to control for confounders.
RESULTS:
The study sample consisted of 220 post-mastectomy patients, 146 (66.1%) awaiting DBR, and 75 who received IBR with expander-implants. The sample was aged 50.6±9.1 (range 30 to 76) and completed the BREAST-Q an average of 2.5 years following mastectomy. Receipt of IBR and no hormone therapy were significant predictors of higher sexual and psychosocial well-being scores after controlling for BMI, age, marital status, children, alcohol consumption, adjuvant radiation and lymphedema (IBR p<0.001; no hormone therapy p=0.017; R2=0.29).
CONCLUSIONS:
Patients awaiting DBR reported significantly lower psychosocial and sexual well-being scores of the BREAST-Q, when compared with a matched cohort of IBR patients. This suggests that patients pursuing DBR may experience a preventable decrease in quality of life.
Learning Objective:
This research will potentially provide clinicians with evidence on which to base decisions after breast cancer diagnosis.